Siemens Named Leader in IDC Life Sciences Assessment
The 2026 IDC MarketScape recognized Siemens for its lab technology and consulting portfolio across the life sciences R&D sector.
Updated on Nov. 5, 2026 in Biotech
Siemens was named a Leader in the 2026 IDC MarketScape Worldwide Life Sciences R&D Lab of the Future Technology Solutions and Consulting Services assessment. The report highlighted case studies with GSK and AstraZeneca.
Why it matters
The assessment evaluates vendors on current capabilities and strategy over the next three to five years, signaling how digital and AI-enabled lab tools are being judged by industry analysts. For pharmaceutical developers, such rankings help frame choices in digital twin and lab automation investments.
The GSK digital twin for adjuvant technologies cut physical experiments by 25 per cent, while Siemens' Smart Lab Ecosystem is cited with a 31% superior local air change rate and 29% faster particle removal. The report does not disclose the full scoring methodology behind the Leader designation.
The players
Siemens
Siemens is a German industrial conglomerate that has expanded its digital twin, automation and AI portfolio into life sciences laboratories and manufacturing.
GSK
GSK is a British multinational pharmaceutical company that has adopted digital twin and virtual testing tools in its vaccine development and manufacturing.
AstraZeneca
AstraZeneca is a British-Swedish multinational biopharmaceutical company that applies process modelling to tablet manufacturing design.
The details
Siemens' open, vendor-agnostic Smart Lab Ecosystem enables plug-and-play composition of room segments, devices and sensors, and its Enterprise Recipe Management approach is built on the ISA-88 standard. GSK worked with Siemens and Atos to digitalise vaccine development, using AI, SIMATIC SIPAT, TIA Portal and Simcenter, while AstraZeneca used gPROMS process modelling for tablet manufacturing design.
Timeline
2025: Siemens acquired Dotmatics.
2026: IDC MarketScape named Siemens a Leader in its life sciences R&D lab assessment.
The Tech Race
Siemens' recognition extends the use of pharmaceutical digital twins from isolated experiments toward integrated lab ecosystems. It places Siemens alongside rival lab-technology vendors competing to supply the life sciences sector's digital transformation.
For patients, the practical result of faster lab design and digital twin testing may appear later as quicker development timelines for new medicines, though no specific product timing is stated. Researchers and lab managers evaluating vendors can use analyst rankings like this one as a reference point when comparing technology options.
The takeaway
Digital twins and modular lab ecosystems are emerging as practical tools for cutting experiment counts and speeding lab construction in pharmaceutical R&D. Organizations weighing these investments can benchmark vendor claims against published case results.
Further reading
For more on how digital tools are reshaping drug development, explore Biotech coverage.
Source note: This article includes information reported by Manufacturingchemist.
